Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report released on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on MRNS. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $4.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Jefferies Financial Group restated a “hold” rating and set a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Finally, TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Nine research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $0.32 on Tuesday. Marinus Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $11.26. The firm has a fifty day moving average price of $0.98 and a 200-day moving average price of $1.24. The company has a market cap of $17.91 million, a price-to-earnings ratio of -0.13 and a beta of 1.26.

Institutional Trading of Marinus Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. lifted its stake in Marinus Pharmaceuticals by 34.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after purchasing an additional 1,219,871 shares in the last quarter. World Investment Advisors LLC purchased a new stake in Marinus Pharmaceuticals in the 3rd quarter worth $104,000. Jacobs Levy Equity Management Inc. lifted its stake in Marinus Pharmaceuticals by 39.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares in the last quarter. Suvretta Capital Management LLC raised its position in shares of Marinus Pharmaceuticals by 32.8% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after buying an additional 1,253,901 shares in the last quarter. Finally, GSA Capital Partners LLP raised its position in shares of Marinus Pharmaceuticals by 409.4% during the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after buying an additional 817,050 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.